C反应蛋白与动脉粥样硬化

[1] Novel clinical markers of vascular wall inflammation. Blake GJ,Ridker PM. Circulation Research . 2001

[2] Vascular smooth muscle cell activation by C-reactive protein. Hattori Y,Matsumura M,Kasai KK,et al. Cardiovascular Research . 2003

[3] Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerosis lesion. Torzewski M,Klouche M,Hock J,et al. Journal of Atheroscler Thromb . 1998

[4] Complement and atherosclerosis: binding of CRP to degraded, non-oxidized LDL enhances complement activation. Bhakdi S,Torzewski M,Klouche M,et al. Journal of Atheroscler Thromb . 1999

[5] Hyperglycemia potentiates the proatherogenic effects of C-Reactive Protein with rosiglitozone. Verma S,Wang CH,Weisel RD,et al. Journal of Molecular and Cellular Cardiology . 2003

[6] The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. Liuzzo G,Biasucci LM,Gallimore JR,et al. The New England Journal of Medicine . 1994

[7] C-reactive protein in healthy subjects: assosiation with obesity, insulin resistence,and endothelial dysfunction. Yudkin JS,Stehouwer CD,Emeris JJ,et al. A potential role for cytokine originating from adipose tissue?Atheroscler Thromb Vasc Biol . 1999

[8] Elevated levels of Creactive protein at discharge in patients with unstable angina predicts recurrent instability. Biasucci LM,Liuzzo G,Grillo RL,et al. Circulation . 1999

[9] Predictive value of Creactive protein after successful coronary artery stenting in patients with stable angina. Gaspardone A,Grea F,Versaci F,et al. The American Journal of Cardiology . 1998

[10] Prospective study of C-reactive protein and the risk of future cardiovascular events among aparently healthy women. Ridker PM,Burug JE,Shih J,et al. Circulation . 1998

[1] Novel clinical markers of vascular wall inflammation. Blake GJ,Ridker PM. Circulation Research . 2001

[2] Vascular smooth muscle cell activation by C-reactive protein. Hattori Y,Matsumura M,Kasai KK,et al. Cardiovascular Research . 2003

[3] Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerosis lesion. Torzewski M,Klouche M,Hock J,et al. Journal of Atheroscler Thromb . 1998

[4] Complement and atherosclerosis: binding of CRP to degraded, non-oxidized LDL enhances complement activation. Bhakdi S,Torzewski M,Klouche M,et al. Journal of Atheroscler Thromb . 1999

[5] Hyperglycemia potentiates the proatherogenic effects of C-Reactive Protein with rosiglitozone. Verma S,Wang CH,Weisel RD,et al. Journal of Molecular and Cellular Cardiology . 2003

[6] The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. Liuzzo G,Biasucci LM,Gallimore JR,et al. The New England Journal of Medicine . 1994

[7] C-reactive protein in healthy subjects: assosiation with obesity, insulin resistence,and endothelial dysfunction. Yudkin JS,Stehouwer CD,Emeris JJ,et al. A potential role for cytokine originating from adipose tissue?Atheroscler Thromb Vasc Biol . 1999

[8] Elevated levels of Creactive protein at discharge in patients with unstable angina predicts recurrent instability. Biasucci LM,Liuzzo G,Grillo RL,et al. Circulation . 1999

[9] Predictive value of Creactive protein after successful coronary artery stenting in patients with stable angina. Gaspardone A,Grea F,Versaci F,et al. The American Journal of Cardiology . 1998

[10] Prospective study of C-reactive protein and the risk of future cardiovascular events among aparently healthy women. Ridker PM,Burug JE,Shih J,et al. Circulation . 1998